About: Harnessing cooperative immune augmentation by contact allergens to enhance the efficacy of viral vaccines

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Harnessing cooperative immune augmentation by contact allergens to enhance the efficacy of viral vaccines Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Harnessing cooperative immune augmentation by contact allergens to enhance the efficacy of viral vaccines
Creator	White, Ian John', St Basketter, David Cunningham, Louise Ferguson, Felicity Kimber, Ian Mcfadden, John
Source	PMC
abstract	Although the development of successful vaccines against coronaviruses may be achieved, for some individuals the immune response that they stimulate may prove to be insufficient for effective host defence. The principle that a relatively strong contact allergen will have an enhancing effect on sensitisation to a less potent contact allergen if they are co‐administered, may not at first appear relevant to this issue. However, this augmentation effect is thought to be due to the sharing of common or complementary pathways. Here we consider briefly aspects of the shared and complementary pathways between skin sensitisation induced by exposure to a contact allergen and the immune response to viruses, with particular reference to Covid‐19. This relationship leads us to explore whether this principle, which we name here as ‘cooperative immune augmentation’ may extend to include viral vaccination. We consider evidence that even relatively weak contact allergens, used in vaccines for other purposes, can show enhanced sensitisation, which is in keeping with a cooperative augmentation principle. Finally, we consider how the potent contact allergen diphenylcyclopropenone could be employed safely as an enhancer of vaccine responses. This article is protected by copyright. All rights reserved.
has issue date	2020-08-09(xsd:dateTime)
bibo:doi	10.1111/cod.13685
has license	no-cc
sha1sum (hex)	b8570b637dc0affe7b9175a9edc3451a2eafe286
schema:url	https://doi.org/10.1111/cod.13685
resource representing a document's title	Harnessing cooperative immune augmentation by contact allergens to enhance the efficacy of viral vaccines
has PubMed Central identifier	PMC7436419
schema:publication	Contact Dermatitis
resource representing a document's body	covid:b8570b637dc0affe7b9175a9edc3451a2eafe286#body_text
is schema:about of	named entity 'leads' named entity 'responses' named entity 'enhancing' named entity 'augmentation' named entity 'enhance' named entity 'allergens' named entity 'LEADS' named entity 'IMMUNE RESPONSE' named entity 'HOW' named entity 'INDIVIDUALS' named entity 'ALLERGENS' named entity 'DEVELOPMENT' named entity 'allergens' named entity 'vaccine' named entity 'protected by copyright' named entity 'vaccines' named entity 'immune response' named entity 'contact allergen' named entity 'vaccines' named entity 'skin reactions' named entity 'vaccine' named entity 'coronaviruses' named entity 'potencies' named entity 'desquamation' named entity 'vesicles' named entity 'Th1' named entity 'neomycin' named entity 'allergic' named entity 'antigens' named entity 'contact allergen' named entity 'antigen' named entity 'virus' named entity 'antigen' named entity 'memory response' named entity 'Finland' named entity 'adjuvant' named entity 'vaccination' named entity 'mercury' named entity 'infection' named entity 'immunogenicity' named entity 'sensitisers' named entity 'antigens' named entity 'immunological effects' named entity 'cobalt' named entity 'mice' named entity 'immune response' named entity 'immunotherapy' named entity 'thimerosal' named entity 'verrucae' named entity 'danger signals' named entity 'antigen' named entity 'vaccination' named entity 'formaldehyde' named entity 'vaccine' named entity 'mice' named entity 'Bonefeld' named entity 'adjuvants' named entity 'mercury' named entity 'urticaria' named entity 'MERS' named entity 'allergen' named entity 'neomycin' named entity 'vaccination' named entity 'aluminium' named entity 'aluminium salts' named entity 'immune responses' named entity 'allergens' named entity 'vaccine' named entity 'nickel' named entity 'Danger signals' named entity 'sensitiser' named entity 'Neomycin' named entity 'pathogenic microorganisms' named entity 'vaccine' named entity 'immunological memory' named entity 'allergens' named entity 'Th1'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software